Carisma Therapeutics Inc.
$ 0.05
0.66%
24 Feb - close price
- Market Cap 1,924,900 USD
- Current Price $ 0.05
- High / Low $ 0.05 / 0.04
- Stock P/E 0.24
- Book Value -0.02
- EPS 0.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.33 %
- ROE -3.63 %
- 52 Week High 1.27
- 52 Week Low 0.03
About
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. The company is headquartered in Philadelphia, Pennsylvania.
Analyst Target Price
$1.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-07 | 2025-05-07 | 2025-03-31 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-02-28 |
| Reported EPS | 1.07 | -0.23 | -0.4224 | -0.42 | -0.31 | -0.27 | -0.46 | -0.52 | -0.53 | -0.49 | -1.93 | -0.8 |
| Estimated EPS | -0.57 | -0.53 | -0.12 | -0.1625 | -0.26 | -0.3 | -0.43 | -0.55 | -0.57 | -0.6 | -0.89 | -2.2 |
| Surprise | 1.64 | 0.3 | -0.3024 | -0.2575 | -0.05 | 0.03 | -0.03 | 0.03 | 0.04 | 0.11 | -1.04 | 1.4 |
| Surprise Percentage | 287.7193% | 56.6038% | -252% | -158.4615% | -19.2308% | 10% | -6.9767% | 5.4545% | 7.0175% | 18.3333% | -116.8539% | 63.6364% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.36147078 | $0.36 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CARM
2025-12-23 00:09:23
This page provides a comprehensive resource for investors and traders to access Carisma Therapeutics SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. Stock Titan uses AI to simplify these complex documents, offering summaries, annotations, and real-time alerts for critical information like insider transactions and executive compensation, aiding in quicker and smarter investment decisions. Recent filings indicate a proposed reverse stock split and a merger with OrthoCellix, Inc. to ensure Nasdaq listing compliance and provide an alternative to liquidation for Carisma Therapeutics.
2025-12-12 18:09:37
Carisma Therapeutics Inc. (OTCID: CARM) is voluntarily delisting its common stock from Nasdaq and deregistering its shares with federal regulators due to long-standing compliance issues, including failure to meet minimum bid price and market value requirements. This move accelerates its withdrawal from public reporting as the company plans an orderly wind-down of operations. The formal delisting is expected around December 25, 2025, and full deregistration 90 days after associated SEC filings.
2025-12-06 04:09:28
Carisma Therapeutics (CARM) announced its Board approved a voluntary delisting from Nasdaq and planned SEC deregistration, aiming to suspend and terminate Exchange Act reporting due to noncompliance with Nasdaq listing rules. Trading of its common stock moved to the OTCID market tier on October 13, 2025. The company expects to file a Form 25 around December 15, 2025, with formal delisting effective by December 25, 2025, and a subsequent Form 15 filing to terminate reporting obligations within 90 days.
2025-12-06 03:44:04
Carisma Therapeutics Inc. (CARM) has announced its intention to voluntarily delist its common stock from The Nasdaq Stock Market LLC and deregister with the SEC. This decision follows a delist determination letter from Nasdaq due to noncompliance with listing rules, leading to the company's stock being suspended from Nasdaq trading and moving to the OTCID market. Carisma expects the formal delisting to occur around December 25, 2025, and will file a Form 15 to terminate its reporting obligations under the Exchange Act as it pursues an orderly wind down of operations.
2025-12-06 03:44:04
Carisma Therapeutics Inc. announced its voluntary delisting from Nasdaq and deregistration with the SEC following noncompliance with listing requirements and a significant stock price decline. The company, which was valued at $2.18 million with its stock at $0.05, plans to file Form 25 around December 15 and Form 15 to suspend its reporting obligations. This decision was made as the biotechnology company pursues an orderly wind-down of its operations.
2025-12-05 11:16:00
Carisma Therapeutics Inc. has announced its intention to voluntarily delist its common stock from Nasdaq and deregister with the SEC, suspending and terminating its reporting obligations. This decision follows a delist determination from Nasdaq due to noncompliance with listing rules, with the company's stock already trading on the OTCID market. Carisma plans to file a Form 25 by December 15, 2025, and a Form 15 thereafter to finalize deregistration and focus on an orderly wind-down of operations.
